Curanex Pharmaceuticals Inc Common Stock (CURX)
Oxford Ledge is still expanding full research coverage of CURX. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
SEC filings
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-05-14
- 10-Q Quarterly financial report (unaudited) 2026-05-14
- 8-K Other material event 2026-05-07
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-04-02
- 10-K Annual financial report with audited statements 2026-03-30
Source: SEC EDGAR.
Annual results
2 years of annual figures for CURX, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$4.2M | -$0.17 |
| 2024 | — | -$361,506 | -$0.03 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
- Open CURX in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.